dalteparin has been researched along with Clinical Deterioration in 1 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
Clinical Deterioration: A critical disease progression, often measured by a set of clinical parameters, which activates HOSPITAL RAPID RESPONSE TEAM.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ferguson, K | 1 |
| Quail, N | 1 |
| Kewin, P | 1 |
| Blyth, KG | 1 |
1 other study available for dalteparin and Clinical Deterioration
| Article | Year |
|---|---|
COVID-19 associated with extensive pulmonary arterial, intracardiac and peripheral arterial thrombosis.
Topics: Anticoagulants; Betacoronavirus; Clinical Deterioration; Computed Tomography Angiography; Coronaviru | 2020 |